BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd., UK  submitted on 8 July 1998 an application for Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Prometax hard capsules, through the centralised procedure.  
This submission concerns an abridged application for four strengths of Prometax hard capsules,  
1.5 mg, 3 mg, 4.5 mg, 6 mg. The application has been made in accordance with Chapter II,  
Article  4.8(a)(i)  of  Council  Directive  65/65/EEC  of  26  January  1995  as  amended.  The  marketing 
authorisation  holder  of  Exelon  hard  capsules,  Novartis  Europharm  Limited,  UK,  consented  to  the 
pharmacological, toxicological and clinical data contained in the original file for Exelon to be used for 
the purpose of examining this application.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. E. Abadie 
Co-Rapporteur:   Dr. P. Sjöberg 
Licensing status 
The product, under the trade name Exelon, was authorised in the EU through the centralised procedure 
on 12 May 1998. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
The procedure started on 24 July 1998. 
The Rapporteur's assessment report was circulated to all CPMP Members on 31 August 1998.  
During  the  meeting  on  16-17  September  1998  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  discussion  within  the  Committee,  issued  a  positive  opinion  (majority)  for 
granting a Marketing Authorisation for Prometax hard capsules on 16 September 1998. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 4 December 1998. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
